Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Obesity Drug Developers Aim To Navigate Regulatory Backroads

Apr 01 2011

• By Emily Hayes

Related Content

FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs

Aug 24 2009

FDA Will Soon Finalize Obesity Guidance, May Tackle CV Safety Separately

Apr 15 2009

Will A CV Warning On Meridia Alter FDA Views On Obesity Drugs?

Nov 30 2009

GlaxoSmithKline's OTC Garage Sale Includes <i>alli</i>, <i>FiberChoice</i>

Apr 18 2011

<i>Egrifta</i> Approval: FDA Balanced Modest Efficacy, Off-Label Use Potential With Unmet Medical Need

Feb 01 2011

Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave

Feb 01 2011

SCOUT Shows Challenges Of Cardiovascular Outcomes Trials In Obesity

Sep 20 2010

Further Phase III Data May Not Help Approvability Of Arena’s Lorcaserin

Nov 01 2010

Panel Continues To Push For Obesity CV Guidance As It Backs <i>Contrave</i> Approval

Dec 13 2010

Vivus Would Market Qnexa With Pregnancy Category X Designation If Approved

Mar 04 2011

Obesity Drug Developers Go With The Gut: R&D Hopes Focus On Locally Acting Agents

Apr 01 2011

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window